Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-04
2008-03-04
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C548S543000, C548S533000, C548S311100, C548S356100, C548S492000, C546S183000, C546S189000, C546S286000
Reexamination Certificate
active
07338976
ABSTRACT:
This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using heterocyclic esters and amides.
REFERENCES:
patent: 4070361 (1978-01-01), Petrillo, Jr.
patent: 4310461 (1982-01-01), Krapcho et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4390695 (1983-06-01), Krapcho et al.
patent: 4531964 (1985-07-01), Shimano et al.
patent: 4574079 (1986-03-01), Gavras et al.
patent: 4578474 (1986-03-01), Krapcho et al.
patent: 4593102 (1986-06-01), Shanklin, Jr.
patent: 4808573 (1989-02-01), Gold et al.
patent: 4818749 (1989-04-01), Gold et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 5011844 (1991-04-01), Fehr
patent: 5147877 (1992-09-01), Goulet
patent: 5189042 (1993-02-01), Goulet et al.
patent: 5192773 (1993-03-01), Armistead et al.
patent: 5194434 (1993-03-01), Chiou et al.
patent: 5198454 (1993-03-01), Chiou et al.
patent: 5244902 (1993-09-01), Sharpe et al.
patent: 5252319 (1993-10-01), Babcock et al.
patent: 5252579 (1993-10-01), Skotnicki et al.
patent: 5258389 (1993-11-01), Goulet et al.
patent: 5284826 (1994-02-01), Eberle
patent: 5294603 (1994-03-01), Rinehart
patent: 5319098 (1994-06-01), Burbaum et al.
patent: 5330993 (1994-07-01), Armistead et al.
patent: 5359138 (1994-10-01), Takeuchi et al.
patent: 5368865 (1994-11-01), Asakura et al.
patent: 5387589 (1995-02-01), Kulkarni
patent: 5414083 (1995-05-01), Hackl et al.
patent: 5424454 (1995-06-01), Burbaum et al.
patent: 5441937 (1995-08-01), Wallace et al.
patent: 5441977 (1995-08-01), Russo et al.
patent: 5447915 (1995-09-01), Schreiber et al.
patent: 5457111 (1995-10-01), Luly et al.
patent: 5468752 (1995-11-01), Freeman
patent: 5514686 (1996-05-01), Mochizuki et al.
patent: 5516797 (1996-05-01), Armistead et al.
patent: 5527533 (1996-06-01), Tso et al.
patent: 5532248 (1996-07-01), Goulet et al.
patent: 5543423 (1996-08-01), Zelle et al.
patent: 5614547 (1997-03-01), Hamilton et al.
patent: 5620921 (1997-04-01), Sullivan
patent: 5631017 (1997-05-01), Sharpe et al.
patent: 5632984 (1997-05-01), Wong
patent: 5641749 (1997-06-01), Yan et al.
patent: 5641750 (1997-06-01), Louis
patent: 5667968 (1997-09-01), LaVail et al.
patent: 5688765 (1997-11-01), Sullivan
patent: 5693645 (1997-12-01), Sharpe et al.
patent: 5700909 (1997-12-01), O'Brien
patent: 5703088 (1997-12-01), Sharpe et al.
patent: 5736516 (1998-04-01), Louis
patent: 5786378 (1998-07-01), Hamilton et al.
patent: 3508251 (1986-09-01), None
patent: 3931051 (1990-03-01), None
patent: 4015255 (1991-11-01), None
patent: 12401 (1980-06-01), None
patent: 48159 (1982-03-01), None
patent: 50800 (1982-05-01), None
patent: 73143 (1983-03-01), None
patent: 88350 (1983-09-01), None
patent: 196841 (1986-10-01), None
patent: 260118 (1988-03-01), None
patent: 333174 (1989-09-01), None
patent: 352000 (1990-01-01), None
patent: 378318 (1990-07-01), None
patent: 405994 (1991-01-01), None
patent: 419049 (1991-03-01), None
patent: 468339 (1992-01-01), None
patent: 572365 (1993-12-01), None
patent: 652229 (1995-05-01), None
patent: 2247456 (1992-03-01), None
patent: 04149166 (1992-05-01), None
patent: 05178824 (1993-07-01), None
patent: WO8809789 (1988-12-01), None
patent: WO9012805 (1990-11-01), None
patent: WO9104985 (1991-04-01), None
patent: WO9113088 (1991-09-01), None
patent: WO9200278 (1992-01-01), None
patent: WO9203472 (1992-03-01), None
patent: WO9204370 (1992-03-01), None
patent: WO9216501 (1992-10-01), None
patent: WO9218478 (1992-10-01), None
patent: WO9219593 (1992-11-01), None
patent: WO9219745 (1992-11-01), None
patent: WO9221313 (1992-12-01), None
patent: WO9307269 (1993-04-01), None
patent: WO9313066 (1993-07-01), None
patent: WO9323548 (1993-11-01), None
patent: WO9325546 (1993-12-01), None
patent: WO9405639 (1994-03-01), None
patent: WO9407858 (1994-04-01), None
patent: WO9413629 (1994-06-01), None
patent: WO9512572 (1995-05-01), None
patent: WO9524385 (1995-09-01), None
patent: WO9526337 (1995-10-01), None
patent: WO9535308 (1995-12-01), None
patent: WO9535367 (1995-12-01), None
patent: WO9606097 (1996-02-01), None
patent: WO9615101 (1996-05-01), None
patent: WO9617816 (1996-06-01), None
patent: WO9603318 (1996-10-01), None
patent: WO9633184 (1996-10-01), None
patent: WO9633187 (1996-10-01), None
patent: WO9636630 (1996-11-01), None
patent: WO9820891 (1998-05-01), None
patent: WO9820892 (1998-05-01), None
patent: WO9820893 (1998-05-01), None
patent: WO9824805 (1998-06-01), None
patent: WO 9827975 (1998-07-01), None
patent: 9207782 (1993-04-01), None
Teri, Linda, et al., Imipramine in the Treatment of Depressed Alzheimer's Patients: Impact on Cognition, Journal of Gerontiology, 1991, pp. P372-P377, vol. 46, n. 6.
Ando, Takao et al., “Formation of Crossed Phenzine from the Reaction between Tetra-p-anisyl- and Tetra-p-tolyl-hydrazines in Liquid Sulphur Dioxide,” Chem. Comm., S. Chem. Comm., 1975, 989.
Andrus, Merrit B., “Structure-based design of an acyclic ligand that bridges FKBP12 and calcineurin,” J. Am. Chem. Soc., 1993, 115(2), 10420-1.
Armistead, D.M. et al., “Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protin for the immunosuppressant FK506,” Acta Crystallogr. 1995, D51(4), 522-8.
Askin, D. et al., “Chemistry of FK-506: benzilic acid rearrangement of the tricarbonyl system,” Tetrahedron Lett., 1989, 30(6), 671-4.
Askin, D. et al., “Effecient Degradation of FK-506 to a versatile synthetic intermediate,” J. Org. Chem., 1990, 55(20), 5451-4.
Baader, Ekkehard et al., “Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues,” Biochem. J., 1994, 300(2), 525-30.
Baumann, K. et al., “Synthesis and oxidative cleavage of the major equilibrium products of ascomycin and Fk 506,” Tetrahedron Lett., 1995, 26(13), 2231-4.
Bender, D., et al., “Periodate oxidation of α-keto γ-lactams. Enol oxidation and β-lactam formation. Mechanism of periodate hydroxylation reactions,” J. Org. Chem., 1978, 43(17), 3354-62.
Birkenshaw, T.N. et al., “Synthetic FKBP12 Ligands. Design and Synthesis of Pyranose Replacements,”Bioorganic&Medicinal Chemistry Letters, (1994) 4:21, 2501-2506.
Boulmedais, Ali et al., “Stereochemistry of Electrochemical Reduction of Optically Active α-ketoamides. II. Electroreduction of benzoylformamides derived from S-(-)-proline,” Bull. Soc. Chim. Fr., 1989, (2), 185-91. (French).
Cameron, Andrew et al., “Immunophilin FK506 binding protein associated with inositol 1,4,5-triphosphate receptor modulates calcium flux,” Proc. Natl. Acad. Sci. USA, 1995, 92, 1784-1788.
Caufield, Craig E. and Musser, John H., “Macrocyclic Immunomodulators,”Annual Reports in Medicinal Chemistry, Johns (Ed.), Academic Press, Chapter 21, 195-204, 1989.
Caffrey, M.V. et al., “Synthesis and Evaluation of Dual Domain Macrocyclic FKBP12 Ligands,”Bioorganic&Medicinal Chemistry Letters, (1994) 4:21, 2507-2510.
Chakraborty, TK et al., “Design and Synthesis of a rapamycin-based high affinity binding FKBP12 ligand,” Chem. Biol., 1995, 2(3), 157-61.
Chakaraborty, Tushar K., “Studies towards the development of cyclic peptide-based analogs of macrolide immunosuppressants,” Pure Appl. Chem., 1996, 68(3), 565-568.
Coleman, R., and Danishefsky, S., “Degradation and manipulations of the immunosuppressant FK506: preparation of potential synthetic intermediates,” Heterocycles, 1989, 28(1), 157-61.
Colombo, L. et al., “Enantioselective synthesis of secondary alcohols in the presence of chiral ligands,” Tetrahedron, 1982, 38(17), 2725-7.
Cunliffe, C. Jane et al., “Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivatives,” J. Med. Chem., 1992, 35 (14), 2652-8.
Cushman, D.W. et al., “Design of potent competitive inhibitor
Hamilton Gregory S.
Ross Douglas T.
Steiner Joseph P.
Foley & Lardner LLP
GPI Nil Holdings Inc.
Lewis Patrick
LandOfFree
Heterocyclic esters or amides for vision and memory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic esters or amides for vision and memory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic esters or amides for vision and memory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2795945